| Summary: | Xianbo Huang,1 Wenbin Qian,2 Xiujin Ye1 1Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, People’s Republic of China; 2Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, People’s Republic of ChinaCorrespondence: Xiujin Ye Tel +86-571-87235875Fax +86-571-87235560;Email yxjsunny@zju.edu.cnWenbin Qian Tel/Fax +86-571-89713674Email qianwb@zju.edu.cnAbstract: Diffuse large B-cell lymphoma (DLBCL) is a complex and aggressive malignancy originating from B lymphocytes and characterized by extensive clinical, phenotypic and molecular heterogeneity. Although research conducted over the past decades has substantially improved our understanding of DLBCL, its pathogenesis has not yet been fully elucidated. The development of RNA sequencing technology has allowed the identification of numerous long noncoding RNAs (lncRNAs) that exhibit aberrant expression in DLBCL. These lncRNAs play crucial roles in DLBCL development and pathogenesis and are thus good candidates for use as diagnostic biomarkers or therapeutic targets. In this review, we describe the lncRNAs associated with DLBCL, summarize their characteristics and molecular functions, and discuss their relationships with clinical practice.Keywords: diffuse large B-cell lymphoma, long noncoding RNA, biomarkers
|
|---|
